FDA And Nuwellis Address Potentially High-Risk Issue With Blood Circuit Device
Benzinga (Tue, 31-Dec 9:31 AM ET)
Nuwellis Regains Compliance with Nasdaq Listing Requirements
Globe Newswire (Thu, 19-Dec 9:00 AM ET)
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights
Globe Newswire (Mon, 11-Nov 8:00 AM ET)
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds
Globe Newswire (Tue, 5-Nov 9:28 AM ET)
Globe Newswire (Mon, 4-Nov 8:30 AM ET)
Nuwellis Announces Preliminary Results for Third Quarter of 2024
Globe Newswire (Fri, 1-Nov 4:15 PM ET)
Globe Newswire (Thu, 31-Oct 8:00 AM ET)
Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024
Globe Newswire (Wed, 23-Oct 4:15 PM ET)
Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.
Nuwellis trades on the NASDAQ stock market under the symbol NUWE.
As of January 3, 2025, NUWE stock price declined to $1.18 with 193,590 million shares trading.
NUWE has a beta of 2.00, meaning it tends to be more sensitive to market movements. NUWE has a correlation of 0.03 to the broad based SPY ETF.
NUWE has a market cap of $5.16 million. This is considered a Sub-Micro Cap stock.
Last quarter Nuwellis reported $2 million in Revenue and -$1.13 earnings per share. This beat revenue expectation by $7,000 and exceeded earnings estimates by $.15.
In the last 3 years, NUWE traded as high as $6,475.10 and as low as $.92.
The top ETF exchange traded funds that NUWE belongs to (by Net Assets): VXF.
NUWE has underperformed the market in the last year with a return of -95.1%, while the SPY ETF gained +27.8%. In the last 3 month period, NUWE fell short of the market, returning -20.3%, while SPY returned +4.6%. However, in the most recent 2 weeks NUWE has outperformed the stock market by returning +18.0%, while SPY returned +0.1%.
NUWE support price is $1.12 and resistance is $1.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUWE shares will trade within this expected range on the day.